David Dai

Stock Analyst at UBS

(0)
# 5080
Out of 5,377 analysts
26
Total ratings
Success rate
Average return
20 Stocks
Name Action PT Current % Upside Ratings Updated
BPMC Blueprint Medicines
Maintains: Neutral
88 129
128.16 0.66% 2 Jun 5, 2025
IOVA Iovance Biotherapeut...
Downgrades: Neutral
17 2
1.9 5.26% 2 May 16, 2025
CGEM Cullinan Therapeutic...
Maintains: Buy
30 24
7.75 209.68% 2 May 12, 2025
NUVL Nuvalent
Upgrades: Buy
100 100
75.54 32.38% 2 Mar 14, 2025
KURA Kura Oncology
Maintains: Buy
27 14
5.83 140.14% 2 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Sell
24
31.55 -23.93% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
3.84 420.83% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
35
11.75 197.87% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
52.67 36.7% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
23.24 196.9% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
21.37 133.97% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
25.27 137.44% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
37
9.28 298.71% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.64 4275% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
14.85 169.36% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
1.31 2953.44% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
1.76 2740.91% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
31.54 64.87% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017